Category: Patent Trial & Appeal Board
-
USPTO Director Squires continues pro-patent enforcement march: IPR petition institutions remain low, submits first-ever public ITC comments
The United States Patent and Trademark Officeâs low institution rate, together with its first-ever public comments to a United States International Trade Commission (ITC) investigation endorsing the ITC as a forum for adjudicating patents, underline Director John A. Squiresâs pro-patent and pro-patent enforcement agenda.
-
Federal Circuit tells petitioners that IPR denials are unreviewable regardless of reliance on agency guidance in place at time of filing
A precedential decision reinforces the unreviewability of the USPTO Director’s decisions to deny (or vacate a decision to institute) inter partes reviews.
-
AIA & AIA: Director Squires issues America’s Innovation Agency memo to take charge of IPR institution decisions under America Invents Act
USPTO Director John A. Squires wants to put an end to the PTAB’s tendency to institute IPRs for career and institutional motives.
-
USPTO Director Squires proposes rules that would marginalize PTAB IPRs: market value of “born strong” U.S. patents to rise
Director Squires has proposed new rules for the PTAB that do not merely complicate but simply prevent serial challenges to patent, even on different grounds. And not only that.
-
Samsung ordered to pay $445 million in U.S. wireless standards-related infringement dispute: jury verdict
The Eastern District of Texas has issued a jury verdict ordering Samsung to pay over $445 million in damages for infringing four of non-practising entity Collissionâs wireless communication standard-essential patents.
-
Squires on fire: revived patent post-PTAB, declared expert unreliable, took procedural route that may have closed door to appeal
Based on an expert’s lack of credibility in his eyes, Director Squires not only terminated the PTAB proceedings without a remand but also made it difficult (or impossible) to appeal,
-
Federal Circuit partly grants Bayer second chance in defending rivaroxaban patent invalidation campaign
The Federal Circuit has partly affirmed and partly vacated a United States Patent and Trademark Officeâs Patent Trial and Appeal Board decision that deemed one of Bayerâs rivaroxaban-related patents invalid, in a three-year case initiated by rivals Mylan Pharmaceuticals, Teva Pharmaceuticals, and Invagen Pharmaceuticals.
-
USPTO divisionsâ clash over Apple patent invalidation decision undermines âintegrity and consistencyâ, patentee alleges
A petition filed by Proxense against Apple has uncovered an inconsistency in results on substantially similar issues and the same underlying facts between decisions by the United States Patent & Trademark Officeâs Patent Trial and Appeal Board and fellow internal division, the Central Reexamination Unit.
-
USPTO issues more discretionary denials: Intel, Google, Nokia, Ericsson among losing petitioners
The significant inter partes review denials come less than a month after a Unified Patents report found the number of such decisions is three times higher than those under Director Andrei Iancu in 2020.
-
USPTO on pace to quadruple discretionary denials under new interim procedures, report says
Recent data by Unified Patents has found that there were three times more United States Patent & Trademark Officeâs Patent Trial and Appeal Board discretionary denial decisions in Q1 2025 than the last record number of decisions (167 in 2020).